PHT Corporation completed its most successful Q2 in company history on June 30, 2011. The strong, outstanding results reflect the growing worldwide adoption of its market-leading ePRO Systems. PHT is the global innovator in ePRO solutions that maximize the collection of high quality data from clinical trial patients. Total bookings were up 53% in the second quarter of 2011 vs. the same period in the previous year. Total revenues through the first half of the year rose 10% and net income increased by 9% over the same period in 2010. The number of trials deployed increased 38% for the first half of the year vs. the same period in 2010. PHT's strong financial performance demonstrates the increased demand in the clinical research market for collecting high quality patient reported outcome data.
PHT's LogPad®, SitePad®, eSense® and NetPRO™ Systems all were in strong demand during the second quarter as trial sponsors consistently turned to PHT for the industry's most innovative, reliable and easy to use ePRO offerings. There was significant growth for PHT's ePRO solutions across the industry and in key target therapeutic areas including oncology, diabetes, gastrointestinal, and respiratory.
PHT President and CEO Phil Lee said, "Pharmaceutical companies and CROs come to PHT for world-class science, products, support, and cost-efficiency. Sponsors benefit from our in-depth experience, knowledge and best practices culled from hundreds of ePRO trial implementations with patients, sites and trial designs similar to theirs. PHT makes ePRO easy for sponsors, sites and patients."
During Q2 PHT unveiled three major new ePRO and PRO products and capabilities: the ePRO Modality Tool, SmartReports™ and SmartReports Mobile.
HEPA air purifiers fall short in cutting respiratory infections in aged-care facilities